Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 January 2021Website:
http://www.cullinanoncology.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:31:06 GMTDividend
Analysts recommendations
Institutional Ownership
CGEM Latest News
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer (NSCLC) with oncogenic mutations
CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that Chief Executive Officer, Nadim Ahmed, will present at the 42nd Annual J.P. Morgan Healthcare Conference, being held January 8-11, 2024 in San Francisco, CA. Mr. Ahmed's presentation is scheduled for Thursday, January 11, at 10:30 am PST (1:30 pm EST).
Cullinan Oncology's lead therapy is zipalertinib, which is in a trial to treat non-small cell lung cancer. The company has a deep pipeline and published encouraging news regarding preclinical candidate CLN-619 as a pan-cancer treatment.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announced that the first clinical data from its Phase 1 clinical study of CLN-619 in patients with advanced solid tumors will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 2-6.
What type of business is Cullinan Oncology?
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
What sector is Cullinan Oncology in?
Cullinan Oncology is in the Healthcare sector
What industry is Cullinan Oncology in?
Cullinan Oncology is in the Biotechnology industry
What country is Cullinan Oncology from?
Cullinan Oncology is headquartered in United States
When did Cullinan Oncology go public?
Cullinan Oncology initial public offering (IPO) was on 08 January 2021
What is Cullinan Oncology website?
https://www.cullinanoncology.com
Is Cullinan Oncology in the S&P 500?
No, Cullinan Oncology is not included in the S&P 500 index
Is Cullinan Oncology in the NASDAQ 100?
No, Cullinan Oncology is not included in the NASDAQ 100 index
Is Cullinan Oncology in the Dow Jones?
No, Cullinan Oncology is not included in the Dow Jones index
When does Cullinan Oncology report earnings?
The next expected earnings date for Cullinan Oncology is 09 August 2024